Drug Delivery News and Research RSS Feed - Drug Delivery News and Research

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.
MIT researchers devise new way to make complex emulsions

MIT researchers devise new way to make complex emulsions

MIT researchers have devised a new way to make complex liquid mixtures, known as emulsions, that could have many applications in drug delivery, sensing, cleaning up pollutants, and performing chemical reactions. [More]
Gates Foundation awards $2.5 million to support development of vaccine-filled microneedles

Gates Foundation awards $2.5 million to support development of vaccine-filled microneedles

The Georgia Institute of Technology and Micron Biomedical have been awarded $2.5 million in grants from the Bill & Melinda Gates Foundation to advance the development of dissolvable microneedle patches for polio immunization. The patches will be studied to evaluate their potential role as part of the worldwide efforts to eradicate polio. [More]
Scientists use graphene to target, neutralise cancer stem cells

Scientists use graphene to target, neutralise cancer stem cells

University of Manchester scientists have used graphene to target and neutralise cancer stem cells while not harming other cells. [More]
Love hormone has remarkable influence on the intoxicating effect of alcohol

Love hormone has remarkable influence on the intoxicating effect of alcohol

Oxytocin, sometimes referred to as the 'love' or 'cuddle' hormone, has a legendary status in popular culture due to its vital role in social and sexual behaviour and long-term bonding. [More]
MIT chemical engineers develop new type of self-healing hydrogel

MIT chemical engineers develop new type of self-healing hydrogel

Scientists are interested in using gels to deliver drugs because they can be molded into specific shapes and designed to release their payload over a specified time period. However, current versions aren't always practical because must be implanted surgically. [More]
Targeted nanomedicines could help prevent heart attacks caused by atherosclerosis

Targeted nanomedicines could help prevent heart attacks caused by atherosclerosis

Nanometer-sized "drones" that deliver a special type of healing molecule to fat deposits in arteries could become a new way to prevent heart attacks caused by atherosclerosis, according to a study in pre-clinical models by scientists at Brigham and Women's Hospital and Columbia University Medical Center. [More]
Lupin introduces new InspiraChamber VHC under strategic licensing agreement with InspiRX

Lupin introduces new InspiraChamber VHC under strategic licensing agreement with InspiRX

Pharma Major Lupin Limited announced today that its US subsidiary, Lupin Pharmaceuticals Inc. (collectively Lupin) has launched the all new InspiraChamber Anti-Static Valved Holding Chamber (VHC) under a strategic licensing agreement with the New Jersey based respiratory research and development company InspiRX Inc. [More]
Study findings could help scientists better design silicon materials to improve chemotherapy drug delivery

Study findings could help scientists better design silicon materials to improve chemotherapy drug delivery

A team of Israeli and American researchers have found that silicon nanomaterials used for the localized delivery of chemotherapy drugs behave differently in cancerous tumors than they do in healthy tissues. The findings could help scientists better design such materials to facilitate the controlled and targeted release of the chemotherapy drugs to tumors. [More]
Biomedical use of gold nanotubes demonstrated in mouse model of human cancer

Biomedical use of gold nanotubes demonstrated in mouse model of human cancer

Scientists have shown that gold nanotubes have many applications in fighting cancer: internal nanoprobes for high-resolution imaging; drug delivery vehicles; and agents for destroying cancer cells. [More]
Study shows targeted therapeutic after chemotherapy kills transitional cancer cells

Study shows targeted therapeutic after chemotherapy kills transitional cancer cells

Timing may be decisive when it comes to overcoming cancer's ability to evade treatment. By hitting breast cancer cells with a targeted therapeutic immediately after chemotherapy, researchers from Brigham and Women's Hospital (BWH) were able to target cancer cells during a transitional stage when they were most vulnerable, killing cells and shrinking tumors in the lab and in pre-clinical models. [More]
NanoSmart's ANA-conjugated liposomal doxorubicin receives FDA Orphan Drug Designation

NanoSmart's ANA-conjugated liposomal doxorubicin receives FDA Orphan Drug Designation

NanoSmart Pharmaceuticals, Inc., a private pharmaceutical company developing nanoparticle drug delivery platforms, has received Orphan Drug Designation from the Food and Drug Administration for one of its lead candidates, antinuclear antibody (ANA) conjugated liposomal doxorubicin. [More]
New NIH grant to help restore function after spinal cord injury

New NIH grant to help restore function after spinal cord injury

Restoring function after spinal cord injury, which damages the connections that carry messages from the brain to the body and back, depends on forming new connections between the surviving nerve cells. While there are some delicate surgical techniques that reconnect the nerves, researchers are also looking at ways to restore the connections themselves at a cellular level. [More]
New stent for treating cardiovascular disease successfully implanted in patients

New stent for treating cardiovascular disease successfully implanted in patients

A new stent for treating cardiovascular disease that incorporates a polymer invented at Rutgers, The State University of New Jersey, has been implanted in patients for the first time. [More]
Five researchers selected to receive 2015 Avant-Garde Award for HIV/AIDS Research

Five researchers selected to receive 2015 Avant-Garde Award for HIV/AIDS Research

With proposals ranging from innovative therapies to the development of unique organoid models of the brain, five scientists have been selected to receive the 2015 Avant-Garde Award for HIV/AIDS Research from the National Institute on Drug Abuse, part of the National Institutes of Health. The five scientists will each receive $500,000 per year for five years to support their research. [More]

Cohera Medical gets FDA approval to distribute TissuGlu Surgical Adhesive in US

Cohera Medical, Inc.®, a leading innovator and developer of surgical adhesives and sealants, announced today that the U.S. Food and Drug Administration (FDA) has approved its TissuGlu® Surgical Adhesive. [More]
New findings could pave way to develop drug therapies for necrosis-related diseases

New findings could pave way to develop drug therapies for necrosis-related diseases

Strokes, heart attacks and traumatic brain injuries are separate diseases with certain shared pathologies that achieve a common end - cell death and human injury due to hypoxia, or lack of oxygen. [More]
Chili peppers show promise as diet-based supplement

Chili peppers show promise as diet-based supplement

Don't go chomping on a handful of chili peppers just yet, but there may be help for hopeful dieters in those fiery little Native American fruits. [More]
BD reports quarterly revenues of $2.051 billion for first fiscal quarter 2014

BD reports quarterly revenues of $2.051 billion for first fiscal quarter 2014

BD (Becton, Dickinson and Company), a leading global medical technology company, today reported quarterly revenues of $2.051 billion for the first fiscal quarter ended December 31, 2014, representing an increase of 1.8 percent from the prior-year period, or 5.3 percent on a foreign currency-neutral basis. [More]
Researchers devise new technique to deliver cancer treatment

Researchers devise new technique to deliver cancer treatment

A team of researchers has devised a new way to target tumors with cancer-fighting drugs, a discovery that may lead to clinical treatments for cancer patients. [More]
MedImmune, University of Manchester sign new research collaboration

MedImmune, University of Manchester sign new research collaboration

MedImmune, the global biologics research and development arm of AstraZeneca, and The University of Manchester have entered into a new research collaboration to generate cutting-edge protein formulation science. [More]